"Of the thiazolidinediones, is the commonly prescribed Avandia therapy from GlaxoSmithKline, which was released in May 1999. in addition to bone fracture as an Avandia side effect, there are several other risk factors associated with consuming the drug..."
A recent issue of the Canadian Medical Association Journal (CMAJ) reported the results of a study indicating that type 2 diabetes women who consume Avandia (rosiglitazone) or Actos (pioglitazone) are "at an increased risk of non-vertebral fractures with a near doubling in the risk of hip fractures."
The study, which was conducted by researchers at the University of East Anglia in Norwich, evaluated the risks of bone density degradation among women who consumed the diabetic therapy treatment. Of the 13,715 participants involved in 10 radomized clinical trials, a large portion were found to have "a significantly increased risk of fractures," according to the CMAJ article.
Scientists were able to identify an increase in bone mineral density loss among women patients specifically in the lumbar spine, which is the largest movable section of the vertebrae that is located above the tailbone.
The study found no risk of bone density loss among men, but women who were already at risk for developing bone fractures were said to be affected with one out of every 21 women developing the condition, while those women not at a predisposed bone fracture risk were said to be affected with one out of every 55 women developing bone density loss.
Read the new book, The Evidence, However, Is Clear...The Seroxat Scandal
ORDER THE PAPERBACK
'THE EVIDENCE, HOWEVER, IS CLEAR...THE SEROXAT SCANDAL' By Bob Fiddaman
SIGNED COPIES HERE OR UNSIGNED FROM CHIPMUNKA PUBLISHING